A small study found MS patients reported improved quality of life and reduced depression after Ocrelizumab biosimilar treatment ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...

When Shanel Gamboa's legs started to tingle and go numb last fall, she attributed it to working long shifts as a neuroscience nurse with Lehigh Valley Health Network. But one morning in October, ...

MS is an autoimmune disorder in which the immune system attacks myelin, the protective covering of nerve fibres in the brain ...

Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.

For years, researchers have been hopeful they could get under the hood of multiple sclerosis. The neurological condition shows up in over 2.5 million people around the world, but it doesn’t always ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system, including the brain, spinal cord, and optic nerves. The body mistakenly attacks and damages the protective ...

Columnist Ben Hofmeister likens the three battlefield ways to degrade an adversary's abilities to the disruptions caused by ...